Status:
ACTIVE_NOT_RECRUITING
Age and Sex-Specific PREValence of AcqUirEd VALVular Heart DiseasE
Lead Sponsor:
Cardiovascular Research Foundation, New York
Collaborating Sponsors:
CVS Caremark
Hawthorne Effect Inc.
Conditions:
Valvular Heart Disease
Eligibility:
All Genders
65-85 years
Brief Summary
The PREVUE-VALVE study will establish reliable, population-based estimates of Valvular Heart Disease (VHD) prevalence among older Americans and allow for the development and validation of several inno...
Detailed Description
With the aging population, the incidence and prevalence of VHD are increasing in the U.S. and other parts of the developed world. Despite the availability of effective therapies and procedures to trea...
Eligibility Criteria
Inclusion
- Age 65-85
- Ability to provide informed consent
- Stably domiciled in a residence that can be accessed by study personnel
Exclusion
- History of complex congenital heart disease
Key Trial Info
Start Date :
April 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2025
Estimated Enrollment :
2870 Patients enrolled
Trial Details
Trial ID
NCT05357404
Start Date
April 21 2022
End Date
April 1 2025
Last Update
February 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hawthorne Effect
Walnut Creek, California, United States, 94596